The Electronic Common Technical Document (eCTD) is the global standard for regulatory submissions to health authorities. It uses a structured digital format that improves efficiency and consistency across regions, although each region still has its own requirements.
As the world’s second-largest pharmaceutical market, China has rapidly modernized its regulatory system. For life sciences companies, meeting China eCTD requirements is now essential for market entry.
Since early 2023, the National Medical Products Administration (NMPA) has replaced most paper submissions with eCTD for most registration types. By 2025, this requirement expanded to cover a wider range of chemical and biological products. However, China’s eCTD requirements differ in key ways from those in the United States, the European Union, and other regions of the International Council for Harmonisation (ICH).
Understanding how to prepare a compliant submission is essential for market access. This guide outlines key requirements, common challenges, and practical steps to help regulatory and clinical teams effectively manage eCTD compliance in China.
Key China eCTD Requirements
China’s eCTD system is regulated by the National Medical Products Administration (NMPA). While it aligns broadly with the International Council for Harmonisation (ICH) standards, it also includes localized adaptations that companies must follow.
Although China has adopted eCTD, it still follows a localized regulatory framework that requires specific expertise. This means:
- Some submissions need both electronic and administrative components
- Formatting and validation must follow rules set by the Center for Drug Evaluation (CDE)
- Timelines and expectations may differ from Western agencies
Structure of the eCTD (Modules 1–5)
Like other regions, China uses the standard five-module CTD structure defined by the ICH eCTD Specification v3.2.2. However, the contents of these modules must meet local standards:
- Module 1 (Regional Administrative Information): This is where China differs most. Module 1 includes country-specific requirements, such as NMPA-tailored application forms, legal documents and authorizations, local labeling and packaging information, and China-specific regulatory declarations.
- Module 2 (Summaries and Overviews): High-level summaries of quality, nonclinical, and clinical data.
- Module 3 (Quality): Information on drug substance and drug product manufacturing, which must often align with the Chinese Pharmacopoeia.
- Module 4 (Nonclinical Study Reports): Preclinical study data, including pharmacology, toxicology, and pharmacokinetics data.
- Module 5 (Clinical Study Reports): Clinical trial, efficacy, and safety data as well as analyses.
Technical Specifications
China eCTD submissions must meet strict technical standards:
- The XML backbone must follow NMPA specifications (v1.0 or v1.1). It serves as the table of contents and navigation structure for the eCTD submission.
- File naming must comply with regional conventions.
- PDFs must be in PDF/A format, searchable, with working bookmarks and hyperlinks, and include embedded Chinese fonts.
- Document granularity must follow local guidance (proper file splitting).
Submissions are validated before acceptance. Errors in structure or metadata can lead to rejection before review begins.
In many cases, submissions must also be provided on physical media (CD-ROM/DVD), with paper copies submitted shortly after electronic acceptance.
Language Requirements
Language is a major challenge in China’s eCTD compliance. All dossiers for review must be in Simplified Chinese.
- Core documents, especially in Module 1, must be in Chinese.
- Many sections in Modules 2–5 also require translation to be legally valid.
- English versions may be included, but only as a reference. Chinese content is the official version used for review.
- All titles, bookmarks, and navigation elements must be in Chinese.
- Labeling and patient-facing materials must be localized, not just translated.
Direct translation is not enough. Terminology and phrasing must match NMPA expectations. Poor translation can lead to delays or regulatory queries, making specialized eCTD translation services essential for accuracy and compliance.
Step-by-Step Guide to Preparing Your China eCTD Submission
Preparing a compliant submission requires a disciplined approach that starts long before the final publishing phase.
1. Conduct a Gap Analysis
Start by comparing your current global dossier against NMPA requirements. Identify missing China-specific data, such as local clinical trial results or specific CMC (Chemistry, Manufacturing, and Controls) details required by the Chinese Pharmacopoeia.
A structured gap analysis helps prevent last-minute surprises and reduces rework.
2. Organize and Structure Documents
Map your documents to the NMPA-specific folder structure. Key actions include mapping each document to the correct module, ensuring consistent naming, and maintaining version control across teams. Misplacing content, such as putting Module 3 data in Module 2, is a leading cause of technical rejection.
3. Prepare and Standardize Content
Ensure content is consistent and technically compliant. Align terminology across modules, maintain data consistency between summaries and reports, convert PDFs to a searchable format (OCR- Optical Character Recognition), and use proper internal hyperlinks. Any minor inconsistency or formatting issue can lead to validation errors or regulatory queries.
4. Handle Translation and Localization
This is one of the most time-intensive steps. Translation should run in parallel with content preparation, not at the end. All documents across Modules 1 through 5 must be accurately translated and localized.
Use subject-matter experts and maintain a centralized glossary. Ensure terminology aligns with NMPA expectations and recognized standards such as the WHO International Classification of Diseases.
5. Create Metadata and XML Backbone
Use NMPA-compliant publishing software to generate the XML backbone. This file contains the metadata (e.g., application number, submission type) that allows the CDE’s system to process your dossier.
6. Validate the Submission
Run your dossier through an eCTD validation tool configured for NMPA requirements. This checks XML structure, file naming, and hyperlink accuracy. Ensure there are no high-severity errors, as these can lead to immediate rejection before technical review.
7. Publish and Submit
After validation, the eCTD sequence is published with correct numbering (starting from 0000 in China). Submission is then completed via the NMPA/CDE electronic system or, in some cases, through physical media (CD/DVD), depending on current regulatory requirements.
8. Manage Lifecycle Updates
The eCTD is not a one-time submission. It is a lifecycle-based system. After initial submission, you will need to submit amendments, variations, and responses to regulatory queries. Any subsequent amendments or variations must use the correct lifecycle operators (e.g., “Replace,” “Delete,” or “Append”) to maintain a clear regulatory history.
Conclusion
Preparing a China eCTD submission goes beyond digitizing documents. It requires a clear understanding of regulatory expectations, careful planning, and precise execution. High-quality translation, correct structure, and thorough validation help reduce delays and improve approval success.
Navigating compliance in China requires a partner who understands both the technical and linguistic requirements of the NMPA. EC Innovations provides specialized translation and localization services to help life sciences companies produce accurate, compliant, and submission-ready documentation.
Contact us today to discuss how we can support your next regulatory submission and ensure your global market access strategy is a success.
